Suppr超能文献

类器官在推进药物发现和开发中的应用。

Applications of Organoids in Advancing Drug Discovery and Development.

机构信息

Clinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.

The Jackson Laboratory, Bar Harbor, ME, USA.

出版信息

J Pharm Sci. 2024 Sep;113(9):2659-2667. doi: 10.1016/j.xphs.2024.06.016. Epub 2024 Jul 20.

Abstract

Organoids are small, self-organizing three-dimensional cell cultures that are derived from stem cells or primary organs. These cultures replicate the complexity of an organ, which cannot be achieved by single-cell culture systems. Organoids can be used in testing of new drugs instead of animals. Development and validation of organoids is thus important to reduce the reliance on animals for drug testing. In this review, we have discussed the developmental and regulatory aspects of organoids and highlighted their importance in drug development. We have first summarized different types of culture-based organoid systems such as submerged Matrigel, micro-fluidic 3D cultures, inducible pluripotent stem cells, and air-liquid interface cultures. These systems help us understand the intricate interplay between cells and their surrounding milieu for identifying functions of target receptors, soluble factors, and spatial interactions. Further, we have discussed the advances in humanized severe-combined immunodeficiency mouse models and their applications in the pharmacology of immune-oncology. Since regulatory aspects are important in using organoids for drug development, we have summarized FDA and EMA regulations on organoid research to support pre-clinical studies. Finally, we have included some unique studies highlighting the use of organoids in studying infectious diseases, cancer, and fundamental biology. These studies also exemplify the latest technological advances in organoid development resulting in improved efficiency. Overall, this review comprehensively summarizes the applications of organoids in early drug development during discovery and pre-clinical studies.

摘要

类器官是从小鼠或原代器官中提取的、具有自我组织能力的三维细胞培养物。这些培养物复制了器官的复杂性,这是单细胞培养系统无法实现的。类器官可以用于替代动物进行新药测试。因此,类器官的开发和验证对于减少对动物进行药物测试的依赖非常重要。在这篇综述中,我们讨论了类器官的发育和监管方面,并强调了它们在药物开发中的重要性。我们首先总结了不同类型的基于培养的类器官系统,如基质胶培养、微流控 3D 培养、诱导多能干细胞和气液界面培养。这些系统帮助我们理解细胞及其周围环境之间的复杂相互作用,以确定靶受体、可溶性因子和空间相互作用的功能。此外,我们还讨论了人源化严重联合免疫缺陷小鼠模型的进展及其在免疫肿瘤药理学中的应用。由于监管方面在使用类器官进行药物开发中非常重要,我们总结了 FDA 和 EMA 关于类器官研究的规定,以支持临床前研究。最后,我们包括了一些独特的研究,强调了类器官在研究传染病、癌症和基础生物学中的应用。这些研究还例示了类器官开发方面的最新技术进展,从而提高了效率。总的来说,这篇综述全面总结了类器官在发现和临床前研究阶段早期药物开发中的应用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验